Emerging mechanisms for exercise effects on muscle wasting and anabolic resistance

References

[[1]] Cancer facts & figures 2020 | American cancer society.

[[2]] J.L. Brown, M.E. Rosa-Caldwell, D.E. Lee, et al.. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice. J Cachexia Sarcopenia Muscle, 8 (6) ( 2017), pp. 926-938, DOI: 10.1002/jcsm.12232

[[3]] K.C.H. Fearon, D.J. Glass, D.C. Guttridge. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metabol, 16 (2) ( 2012), pp. 153-166, DOI: 10.1016/j.cmet.2012.06.011

[[4]] J.K. Onesti, D.C. Guttridge. Inflammation based regulation of cancer cachexia. BioMed Res Int, 2014 ( 2014), DOI: 10.1155/2014/168407

[[5]] K. Fearon, F. Strasser, S.D. Anker, et al.. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol, 12 (5) ( 2011), pp. 489-495, DOI: 10.1016/S1470- 2045(10)70218-7

[[6]] J.P. Hardee, B.R. Counts, J.A. Carson. Understanding the role of exercise in cancer cachexia therapy. Am J Lifestyle Med, 13 (1) ( 2019), pp. 46-60, DOI: 10.1177/1559827617725283

[[7]] T.S. Solheim, B.J.A. Laird, T.R. Balstad, et al.. Cancer cachexia: rationale for the MENAC (Multimodal—exercise, nutrition and anti-inflammatory medication for cachexia) trial. BMJ Support Palliat Care, 8 (3) ( 2018), pp. 258-265, DOI: 10.1136/bmjspcare-2017-001440

[[8]] T.S. Solheim, B.J.A. Laird, T.R. Balstad, et al.. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle, 8 (5) ( 2017), pp. 778-788, DOI: 10.1002/jcsm.12201

[[9]] E.J. Roeland, K. Bohlke, V.E. Baracos, et al.. Management of cancer cachexia: ASCO guideline. J Clin Oncol, 38 (21) ( 2020), pp. 2438-2453, DOI: 10.1200/JCO.20.00611